Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy.

Martier R, Liefhebber JM, García-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, Ursua S, Petry H, van Deventer SJ, Evers MM, Konstantinova P.

Mol Ther Nucleic Acids. 2019 Feb 11;16:26-37. doi: 10.1016/j.omtn.2019.02.001. [Epub ahead of print]

2.

Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients.

Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I, Petry H, van Deventer SJ, Evers MM, Konstantinova P.

Mol Ther Nucleic Acids. 2019 Mar 1;14:593-608. doi: 10.1016/j.omtn.2019.01.010. Epub 2019 Jan 30.

3.

Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation.

Diesch J, Bywater MJ, Sanij E, Cameron DP, Schierding W, Brajanovski N, Son J, Sornkom J, Hein N, Evers M, Pearson RB, McArthur GA, Ganley ARD, O'Sullivan JM, Hannan RD, Poortinga G.

Commun Biol. 2019 Jan 28;2:39. doi: 10.1038/s42003-019-0284-y. eCollection 2019.

4.

Understanding the Acceptance of an eHealth Technology in the Early Stages of Development: An End-User Walkthrough Approach and Two Case Studies.

van Velsen L, Evers M, Bara CD, Op den Akker H, Boerema S, Hermens H.

JMIR Form Res. 2018 Jun 15;2(1):e10474. doi: 10.2196/10474.

5.

Coping with uncertainty in water management: Qualitative system analysis as a vehicle to visualize the plurality of practitioners' uncertainty handling routines.

Höllermann B, Evers M.

J Environ Manage. 2019 Apr 1;235:213-223. doi: 10.1016/j.jenvman.2019.01.034. Epub 2019 Jan 23.

PMID:
30682674
6.

Immune Effector Functions of Human IgG2 Antibodies against EGFR.

Rösner T, Kahle S, Montenegro F, Matlung HL, Jansen JHM, Evers M, Beurskens F, Leusen JHW, van den Berg TK, Valerius T.

Mol Cancer Ther. 2019 Jan;18(1):75-88. doi: 10.1158/1535-7163.MCT-18-0341. Epub 2018 Oct 3.

PMID:
30282813
7.

High-Content Imaging Approaches to Quantitate Stress-Induced Changes in Nucleolar Morphology.

He JS, Soo P, Evers M, Parsons KM, Hein N, Hannan KM, Hannan RD, George AJ.

Assay Drug Dev Technol. 2018 Aug/Sep;16(6):320-332. doi: 10.1089/adt.2018.861.

PMID:
30148664
8.

The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.

Evers M, Jak M, Leusen JHW.

Expert Opin Biol Ther. 2018 Sep;18(9):973-982. doi: 10.1080/14712598.2018.1508444. Epub 2018 Aug 10. Review.

PMID:
30084674
9.

AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.

Evers MM, Miniarikova J, Juhas S, Vallès A, Bohuslavova B, Juhasova J, Skalnikova HK, Vodicka P, Valekova I, Brouwers C, Blits B, Lubelski J, Kovarova H, Ellederova Z, van Deventer SJ, Petry H, Motlik J, Konstantinova P.

Mol Ther. 2018 Sep 5;26(9):2163-2177. doi: 10.1016/j.ymthe.2018.06.021. Epub 2018 Jun 25.

10.

Simultaneous Opto- and Spectro-Electrochemistry: Reactions of Individual Nanoparticles Uncovered by Dark-Field Microscopy.

Wonner K, Evers MV, Tschulik K.

J Am Chem Soc. 2018 Oct 10;140(40):12658-12661. doi: 10.1021/jacs.8b02367. Epub 2018 Jul 17.

PMID:
29995398
11.

Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.

Toonen LJA, Overzier M, Evers MM, Leon LG, van der Zeeuw SAJ, Mei H, Kielbasa SM, Goeman JJ, Hettne KM, Magnusson OT, Poirel M, Seyer A, 't Hoen PAC, van Roon-Mom WMC.

Mol Neurodegener. 2018 Jun 22;13(1):31. doi: 10.1186/s13024-018-0261-9.

12.

Enhanced quantification of metabolic activity for individual adipocytes by label-free FLIM.

Evers M, Salma N, Osseiran S, Casper M, Birngruber R, Evans CL, Manstein D.

Sci Rep. 2018 Jun 8;8(1):8757. doi: 10.1038/s41598-018-27093-x.

13.

Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer.

Zaytseva YY, Rychahou PG, Le AT, Scott TL, Flight RM, Kim JT, Harris J, Liu J, Wang C, Morris AJ, Sivakumaran TA, Fan T, Moseley H, Gao T, Lee EY, Weiss HL, Heuer TS, Kemble G, Evers M.

Oncotarget. 2018 May 15;9(37):24787-24800. doi: 10.18632/oncotarget.25361. eCollection 2018 May 15.

14.

Assessment of skin lesions produced by focused, tunable, mid-infrared chalcogenide laser radiation.

Evers M, Ha L, Casper M, Welford D, Kositratna G, Birngruber R, Manstein D.

Lasers Surg Med. 2018 Sep;50(9):961-972. doi: 10.1002/lsm.22935. Epub 2018 May 25.

PMID:
29799127
15.

Global burden of neuroendocrine tumors and changing incidence in Kentucky.

Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, Tucker T, Evers M, Arnold S, Anthony LB.

Oncotarget. 2018 Apr 10;9(27):19245-19254. doi: 10.18632/oncotarget.24983. eCollection 2018 Apr 10.

16.

Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".

Evers M, Kruse E, Hamdan F, Lebbink RJ, Leusen JHW.

J Immunol. 2018 Apr 15;200(8):2515-2516. doi: 10.4049/jimmunol.1800087. No abstract available.

PMID:
29632250
17.

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status.

Chauhan A, Arnold SM, Kolesar J, Thomas HE, Evers M, Anthony L.

Oncotarget. 2018 Feb 22;9(18):14738-14740. doi: 10.18632/oncotarget.24553. eCollection 2018 Mar 6.

18.

Deciphering the Surface Composition and the Internal Structure of Alloyed Silver-Gold Nanoparticles.

Grasmik V, Rurainsky C, Loza K, Evers MV, Prymak O, Heggen M, Tschulik K, Epple M.

Chemistry. 2018 Jun 26;24(36):9051-9060. doi: 10.1002/chem.201800579. Epub 2018 Jun 19.

PMID:
29522654
19.

Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature.

Chauhan A, Horn M, Magee G, Hodges K, Evers M, Arnold S, Anthony L.

Oncotarget. 2017 Dec 28;9(10):8801-8809. doi: 10.18632/oncotarget.23753. eCollection 2018 Feb 6.

20.

Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Miniarikova J, Evers MM, Konstantinova P.

Mol Ther. 2018 Apr 4;26(4):947-962. doi: 10.1016/j.ymthe.2018.02.002. Epub 2018 Feb 8. Review.

PMID:
29503201
21.

New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.

Meyer S, Evers M, Jansen JHM, Buijs J, Broek B, Reitsma SE, Moerer P, Amini M, Kretschmer A, Ten Broeke T, den Hartog MT, Rijke M, Klein C, Valerius T, Boross P, Leusen JHW.

Br J Haematol. 2018 Mar;180(6):808-820. doi: 10.1111/bjh.15132. Epub 2018 Feb 22.

PMID:
29468712
22.

Critical evaluation of quantification methods for oligonucleotides formulated in lipid nanoparticles.

Oude Blenke E, Evers MJW, Baumann V, Winkler J, Storm G, Mastrobattista E.

Int J Pharm. 2018 Sep 15;548(2):793-802. doi: 10.1016/j.ijpharm.2017.12.035. Epub 2017 Dec 21.

PMID:
29275035
23.

Polymeric microspheres for the sustained release of a protein-based drug carrier targeting the PDGFβ-receptor in the fibrotic kidney.

Teekamp N, Van Dijk F, Broesder A, Evers M, Zuidema J, Steendam R, Post E, Hillebrands JL, Frijlink HW, Poelstra K, Beljaars L, Olinga P, Hinrichs WLJ.

Int J Pharm. 2017 Dec 20;534(1-2):229-236. doi: 10.1016/j.ijpharm.2017.09.072. Epub 2017 Oct 14.

24.

AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.

Miniarikova J, Zimmer V, Martier R, Brouwers CC, Pythoud C, Richetin K, Rey M, Lubelski J, Evers MM, van Deventer SJ, Petry H, Déglon N, Konstantinova P.

Gene Ther. 2017 Oct;24(10):630-639. doi: 10.1038/gt.2017.71. Epub 2017 Aug 3.

25.

Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.

Hansmann J, Evers MJ, Bui JT, Lokken RP, Lipnik AJ, Gaba RC, Ray CE Jr.

J Vasc Interv Radiol. 2017 Sep;28(9):1224-1231.e2. doi: 10.1016/j.jvir.2017.05.020. Epub 2017 Jul 6.

PMID:
28688815
26.

Epidemiological study of paediatric germ cell tumours revealed the incidence and distribution that was expected, but a low mortality rate.

Evers M, Rechnitzer C, Graem N, Skov Wehner P, Schroeder H, Rosthoej S, Mosbech CH, Hoei-Hansen CE, Sehested A, Treger TD, Brok J.

Acta Paediatr. 2017 May;106(5):779-785. doi: 10.1111/apa.13767. Epub 2017 Feb 22.

PMID:
28135773
27.

Strategies for the Activation and Release of the Membranolytic Peptide Melittin from Liposomes Using Endosomal pH as a Trigger.

Oude Blenke E, Sleszynska M, Evers MJ, Storm G, Martin NI, Mastrobattista E.

Bioconjug Chem. 2017 Feb 15;28(2):574-582. doi: 10.1021/acs.bioconjchem.6b00677. Epub 2017 Jan 13.

PMID:
28004569
28.

Gene silencing pathways found in the green alga Volvox carteri reveal insights into evolution and origins of small RNA systems in plants.

Dueck A, Evers M, Henz SR, Unger K, Eichner N, Merkl R, Berezikov E, Engelmann JC, Weigel D, Wenzl S, Meister G.

BMC Genomics. 2016 Nov 2;17(1):853.

29.

In Planta Determination of the mRNA-Binding Proteome of Arabidopsis Etiolated Seedlings.

Reichel M, Liao Y, Rettel M, Ragan C, Evers M, Alleaume AM, Horos R, Hentze MW, Preiss T, Millar AA.

Plant Cell. 2016 Oct;28(10):2435-2452. Epub 2016 Oct 11.

30.

In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease.

Casaca-Carreira J, Toonen LJA, Evers MM, Jahanshahi A, van-Roon-Mom WMC, Temel Y.

Biomed Pharmacother. 2016 Dec;84:93-96. doi: 10.1016/j.biopha.2016.09.007. Epub 2016 Sep 16.

PMID:
27639545
31.

Correction: Slug Is Increased in Vascular Remodeling and Induces a Smooth Muscle Cell Proliferative Phenotype.

Coll-Bonfill N, Peinado VI, Pisano MV, Párrizas M, Blanco I, Evers M, Engelmann JC, García-Lucio J, Tura-Ceide O, Meister G, Barberà JA, Musri MM.

PLoS One. 2016 Aug 25;11(8):e0162117. doi: 10.1371/journal.pone.0162117. eCollection 2016.

32.

CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.

Oude Blenke E, Evers MJ, Mastrobattista E, van der Oost J.

J Control Release. 2016 Dec 28;244(Pt B):139-148. doi: 10.1016/j.jconrel.2016.08.002. Epub 2016 Aug 4. Review.

PMID:
27498021
33.

Slug Is Increased in Vascular Remodeling and Induces a Smooth Muscle Cell Proliferative Phenotype.

Coll-Bonfill N, Peinado VI, Pisano MV, Párrizas M, Blanco I, Evers M, Engelmann JC, García-Lucio J, Tura-Ceide O, Meister G, Barberà JA, Musri MM.

PLoS One. 2016 Jul 21;11(7):e0159460. doi: 10.1371/journal.pone.0159460. eCollection 2016. Erratum in: PLoS One. 2016;11(8):e0162117.

34.

Integrated hydrologic modeling as a key for sustainable urban water resources planning.

Eshtawi T, Evers M, Tischbein B, Diekkrüger B.

Water Res. 2016 Sep 15;101:411-428. doi: 10.1016/j.watres.2016.05.061. Epub 2016 May 29.

PMID:
27295616
35.

Identification of a new gene regulatory circuit involving B cell receptor activated signaling using a combined analysis of experimental, clinical and global gene expression data.

Schrader A, Meyer K, Walther N, Stolz A, Feist M, Hand E, von Bonin F, Evers M, Kohler C, Shirneshan K, Vockerodt M, Klapper W, Szczepanowski M, Murray PG, Bastians H, Trümper L, Spang R, Kube D.

Oncotarget. 2016 Jul 26;7(30):47061-47081. doi: 10.18632/oncotarget.9219.

36.

Role of miRNAs and alternative mRNA 3'-end cleavage and polyadenylation of their mRNA targets in cardiomyocyte hypertrophy.

Soetanto R, Hynes CJ, Patel HR, Humphreys DT, Evers M, Duan G, Parker BJ, Archer SK, Clancy JL, Graham RM, Beilharz TH, Smith NJ, Preiss T.

Biochim Biophys Acta. 2016 May;1859(5):744-56. doi: 10.1016/j.bbagrm.2016.03.010. Epub 2016 Mar 24.

PMID:
27032571
37.

miRA: adaptable novel miRNA identification in plants using small RNA sequencing data.

Evers M, Huttner M, Dueck A, Meister G, Engelmann JC.

BMC Bioinformatics. 2015 Nov 5;16:370. doi: 10.1186/s12859-015-0798-3.

38.

The emerging epitranscriptomics of long noncoding RNAs.

Shafik A, Schumann U, Evers M, Sibbritt T, Preiss T.

Biochim Biophys Acta. 2016 Jan;1859(1):59-70. doi: 10.1016/j.bbagrm.2015.10.019. Epub 2015 Nov 2. Review.

PMID:
26541084
39.

Rapid fibrin plug formation within cutaneous ablative fractional CO2 laser lesions.

Kositratna G, Evers M, Sajjadi A, Manstein D.

Lasers Surg Med. 2016 Feb;48(2):125-32. doi: 10.1002/lsm.22412. Epub 2015 Sep 21.

PMID:
26388136
40.

COPD inhaler selection--factors to consider.

Straw A, Heins JR, Evers M.

S D Med. 2015 May;68(5):217-9. No abstract available.

PMID:
26058261
41.

Making (anti-) sense out of huntingtin levels in Huntington disease.

Evers MM, Schut MH, Pepers BA, Atalar M, van Belzen MJ, Faull RL, Roos RA, van Roon-Mom WM.

Mol Neurodegener. 2015 Apr 28;10:21. doi: 10.1186/s13024-015-0018-7.

42.

Antisense oligonucleotides in therapy for neurodegenerative disorders.

Evers MM, Toonen LJ, van Roon-Mom WM.

Adv Drug Deliv Rev. 2015 Jun 29;87:90-103. doi: 10.1016/j.addr.2015.03.008. Epub 2015 Mar 20. Review.

43.

Interplay between quantum shells and orientation in quasifission.

Wakhle A, Simenel C, Hinde DJ, Dasgupta M, Evers M, Luong DH, du Rietz R, Williams E.

Phys Rev Lett. 2014 Oct 31;113(18):182502. Epub 2014 Oct 28.

PMID:
25396364
44.

48Ca+249Bk fusion reaction leading to element Z = 117: long-lived α-decaying 270Db and discovery of 266Lr.

Khuyagbaatar J, Yakushev A, Düllmann ChE, Ackermann D, Andersson LL, Asai M, Block M, Boll RA, Brand H, Cox DM, Dasgupta M, Derkx X, Di Nitto A, Eberhardt K, Even J, Evers M, Fahlander C, Forsberg U, Gates JM, Gharibyan N, Golubev P, Gregorich KE, Hamilton JH, Hartmann W, Herzberg RD, Heßberger FP, Hinde DJ, Hoffmann J, Hollinger R, Hübner A, Jäger E, Kindler B, Kratz JV, Krier J, Kurz N, Laatiaoui M, Lahiri S, Lang R, Lommel B, Maiti M, Miernik K, Minami S, Mistry A, Mokry C, Nitsche H, Omtvedt JP, Pang GK, Papadakis P, Renisch D, Roberto J, Rudolph D, Runke J, Rykaczewski KP, Sarmiento LG, Schädel M, Schausten B, Semchenkov A, Shaughnessy DA, Steinegger P, Steiner J, Tereshatov EE, Thörle-Pospiech P, Tinschert K, Torres De Heidenreich T, Trautmann N, Türler A, Uusitalo J, Ward DE, Wegrzecki M, Wiehl N, Van Cleve SM, Yakusheva V.

Phys Rev Lett. 2014 May 2;112(17):172501. Epub 2014 May 1.

PMID:
24836239
45.

Polytrauma at the Emergency Department; can we relate arterial blood gas analysis to a shock classification?

Evers MJ, Vaneker M, Biert J.

Eur J Trauma Emerg Surg. 2014 Apr;40(2):169-73. doi: 10.1007/s00068-013-0325-z. Epub 2013 Sep 10.

PMID:
26815897
46.

The role of big data and advanced analytics in drug discovery, development, and commercialization.

Szlezák N, Evers M, Wang J, Pérez L.

Clin Pharmacol Ther. 2014 May;95(5):492-5. doi: 10.1038/clpt.2014.29. Epub 2014 Feb 20.

PMID:
24642713
47.

Does an aerobic endurance programme have an influence on information processing in migraineurs?

Overath CH, Darabaneanu S, Evers MC, Gerber WD, Graf M, Keller A, Niederberger U, Schäl H, Siniatchkin M, Weisser B.

J Headache Pain. 2014 Feb 14;15:11. doi: 10.1186/1129-2377-15-11.

48.

Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.

Evers MM, Tran HD, Zalachoras I, Meijer OC, den Dunnen JT, van Ommen GJ, Aartsma-Rus A, van Roon-Mom WM.

Nucleic Acid Ther. 2014 Feb;24(1):4-12. doi: 10.1089/nat.2013.0452. Epub 2013 Dec 31.

PMID:
24380395
49.

Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.

Evers MM, Toonen LJ, van Roon-Mom WM.

Mol Neurobiol. 2014 Jun;49(3):1513-31. doi: 10.1007/s12035-013-8596-2. Epub 2013 Nov 29. Review.

50.

Supplemental Content

Support Center